



Innovations in Soft Tissue Sarcoma Diagnosis and Treatment

Guest Editors:

Dr. Erlinda M. Gordon

Sarcoma Oncology Research
Center, Santa Monica, CA 90403,
USA

Dr. Sant P. Chawla

Sarcoma Oncology Research
Center, Santa Monica, CA 90403,
USA

Dr. Frederick L. Hall

Sarcoma Oncology Research
Center, Santa Monica, CA 90403,
USA

Deadline for manuscript
submissions:

closed (30 May 2024)

Message from the Guest Editors

Dear Colleagues,

Recent advances in genetic screening, molecular profiling, targeted therapy, gene therapy and immunotherapy for soft tissue sarcomas (STS) have evoked increasing optimism in the medical and scientific community. Hence, it is time to reflect on the many faces of STS and current innovations in its diagnosis and treatment. STS is a rare cancer involving mesodermal tissues. Surgical resection is the standard of care for localized disease, but its recurrence rate is high and the prognosis for advanced STS is poor, with a median survival of 8–13 months.

This Special Issue entitled "Innovations in Soft Tissue Sarcoma Diagnosis and Treatment" will include review articles, original clinical and translational research articles that are hypothesis-generating toward the development of precision medicine for STS.

Dr. Erlinda M. Gordon

Dr. Sant P. Chawla

Dr. Frederick L. Hall

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)